This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

November 6–8, 2023 | Munich, GermanyNovember 14–15, 2023 | Digital Partnering

T-Cypher Bio


T-Cypher Bio have developed a World-leading discovery platform focused on novel tumour-specific targets. We are exploring novel areas of the intracellular target space and validating unique T-cell Receptors (TCRs) discovered by our platform known as ‘BAIT’. Our oncology targets are shared by broad pools of patients who are beyond the reach of the current TCR target space. We intend to develop our TCRs for deployment through in-house soluble bi-specific agents, as well as through partnering with complementary T-cell therapy and other platforms. Our approach involves high-sensitivity T-cell screening based on proprietary reagents which support the identification of clinically-impactful, rare, T-cell clones through multi-parameter read-outs.